Drug profile · INN
sunitinib malate
SUTENT
sunitinib malate (SUTENT) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — sunitinib malate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
sunitinib malate (SUTENT) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Macrophage colony-stimulating factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sunitinib malate?
sunitinib malate (SUTENT) is a vascular endothelial growth factor receptor inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sunitinib malate?
SUTENT is a marketed brand name for sunitinib malate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sunitinib malate?
sunitinib malate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.